Patient and Community Factors Affecting Treatment Access for Opioid Use Disorder
- PMID: 37473410
- PMCID: PMC10372722
- DOI: 10.1097/AOG.0000000000005227
Patient and Community Factors Affecting Treatment Access for Opioid Use Disorder
Abstract
Objective: To examine whether access to treatment for women with opioid use disorder (OUD) varied by race and ethnicity, community characteristics, and pregnancy status.
Methods: We conducted a secondary data analysis of a simulated patient caller study of buprenorphine-waivered prescribers and opioid-treatment programs in 10 U.S. states. We conducted multivariable analyses, accounting for potential confounders, to evaluate factors associated with likelihood of successfully securing an appointment. Descriptive statistics and significance testing examined 1) caller characteristics and call outcome by assigned race and ethnicity and clinic type (combined, opioid-treatment programs, and buprenorphine-waivered prescribers) and 2) clinic and community characteristics and call outcome by community race and ethnicity distribution (majority White vs majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander) and clinic type. A multiple logistic regression model was fitted to assess the likelihood of obtaining an appointment by callers' race and ethnicity and pregnancy status with the exposure of interest being majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander community distribution.
Results: In total, 3,547 calls reached clinics to schedule appointments. Buprenorphine-waivered prescribers were more likely to be in communities that were more than 50% White (88.9% vs 77.3%, P<.001), and opioid-treatment programs were more likely to be in communities that were less than 50% White (11.1% vs 22.7%, P<.001). Callers were more likely to be granted appointments in majority Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander communities (adjusted odds ratio [aOR] 1.06, 95% CI 1.02-1.10 per 10% Black, Hispanic, Asian, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander community population) and at opioid-treatment programs (aOR 4.94, 95% CI 3.52-6.92) and if they were not pregnant (aOR 1.79, 95% CI 1.53-2.09).
Conclusion: Clinic distribution and likelihood of acceptance for treatment varied by community race and ethnicity distribution. Access to treatment for OUD remains challenging for pregnant people and in many historically marginalized U.S. communities.
Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Financial Disclosure Stephen W. Patrick reports money was paid to his institution from the Center for Medicare & Medicaid Innovation, NICHD, and NIDA. He received additional grants from The Boedecker Foundation, Agency for Healthcare Research and Quality, National Institute of Mental Health, and the Robert Wood Johnson Foundation. The other authors did not report any potential conflicts of interest.
Figures
Similar articles
-
A cross-sectional study of differences in medication for opioid use disorder receipt among pregnant people enrolled in Medicaid in Oregon, United States.Addiction. 2025 May;120(5):997-1006. doi: 10.1111/add.16752. Epub 2025 Jan 10. Addiction. 2025. PMID: 39789947
-
Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic Review.JAMA Health Forum. 2024 Jun 7;5(6):e241388. doi: 10.1001/jamahealthforum.2024.1388. JAMA Health Forum. 2024. PMID: 38848090 Free PMC article.
-
Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.JAMA Netw Open. 2020 May 1;3(5):e205734. doi: 10.1001/jamanetworkopen.2020.5734. JAMA Netw Open. 2020. PMID: 32453384 Free PMC article.
-
Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes.Subst Abuse Treat Prev Policy. 2022 May 25;17(1):41. doi: 10.1186/s13011-022-00457-3. Subst Abuse Treat Prev Policy. 2022. PMID: 35614487 Free PMC article.
-
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Exp Clin Psychopharmacol. 2021 Oct;29(5):524-538. doi: 10.1037/pha0000510. Epub 2021 Jul 5. Exp Clin Psychopharmacol. 2021. PMID: 34242040 Free PMC article.
Cited by
-
"Just Google It": A Qualitative Study of Reproductive-Age Women's Stigmatizing Experiences When Accessing Buprenorphine for Opioid Use Disorder.Womens Health Issues. 2025 Jan-Feb;35(1):45-53. doi: 10.1016/j.whi.2024.10.003. Epub 2024 Nov 26. Womens Health Issues. 2025. PMID: 39603927
-
Pain Neuroscience Education on Reducing Opioid Dependency in African American and Caucasian Populations: A Narrative Review.J Clin Med. 2025 Jun 19;14(12):4360. doi: 10.3390/jcm14124360. J Clin Med. 2025. PMID: 40566105 Free PMC article. Review.
References
-
- NIH NIDA. Overdose Death Rates. National Institute on Drug Abuse. https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates. Published January 20, 2022. Accessed May 2, 2022.
-
- Opioid Use and Opioid Use Disorder in Pregnancy. https://www.acog.org/en/clinical/clinical-guidance/committee-opinion/art.... Accessed February 24, 2022.
-
- Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics. 1976;58(5):681–685. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous